Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016’, provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

The report reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics and enlists all their major and minor projects

The report assesses Methicillin-Resistant Staphylococcus aureus (MRSA) Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Absynth Biologics Limited

Actelion Ltd

Adenium Biotech ApS

AIMM Therapeutics B.V.

Alchemia Limited

Allergan Plc

AlphaMab Co., Ltd

Alvogen Korea Co., Ltd.

AmpliPhi Biosciences Corporation

AnGes MG, Inc.

Antibiotx ApS

Aphios Corporation

Aridis Pharmaceuticals LLC

Arsanis, Inc.

AstraZeneca Plc

Atriva Therapeutics GmbH

Bavarian Nordic A/S

Bharat Biotech International Limited

C3 Jian, Inc

Cellceutix Corporation

Cempra Inc

Citius Pharmaceuticals, Inc.

Common Pharma Inc

ContraFect Corporation

Crestone, Inc.

Critical Outcome Technologies Inc

CrystalGenomics, Inc.

CSA Biotechnologies LLC

Debiopharm International SA

Dermala Inc

DesignMedix, Inc.

Destiny Pharma Limited

Dong-A Socio Holdings Co. Ltd.

e-Therapeutics Plc

Emergent BioSolutions Inc.

Ensol Biosciences Inc.

Excelimmune, Inc.

Galapagos NV

GangaGen Inc.

Gero Corp

Helix BioMedix, Inc.

Hsiri Therapeutics LLC

Ildong Pharmaceutical Co., Ltd.

Immupharma Plc

iNtRON Biotechnology Inc.

ioGenetics, Inc.

Kyorin Pharmaceutical Co., Ltd.

Lascco SA

LegoChem Biosciences, Inc

Lipocure Ltd.

Madam Therapeutics B.V.

Melinta Therapeutics, Inc

Merck & Co., Inc.

Microbiotix, Inc.

MicuRx Pharmaceuticals, Inc.

MorphoSys AG

Motif Bio Plc

Nabriva Therapeutics AG

Nemus Bioscience, Inc.

Novabiotics Limited

NovaDigm Therapeutics, Inc.

NovoBiotic Pharmaceuticals, LLC

Omnia Molecular Ltd.

Oragenics, Inc.

Pfizer Inc.

Phico Therapeutics Limited

Procarta Biosystems Limited

Prommune, Inc.

Recce Pty Ltd

Redx Pharma Plc

Sarepta Therapeutics, Inc.

Savara Inc.

Sealife PHARMA GMBH

Sentinella Pharmaceuticals, Inc.

Sequoia Sciences Inc

Soligenix, Inc.

Sorrento Therapeutics Inc

Taejoon Pharm Co., Ltd.

TAXIS Pharmaceuticals, Inc.

Telephus Medical LLC

Tetraphase Pharmaceuticals Inc.

TGV-Laboratories

Theravance Biopharma Inc

Trellis Bioscience, Inc.

Valevia UK Limited

VLP Biotech, Inc.

Wintermute Biomedical LLC

Wockhardt Limited

XBiotech Inc

Yungjin Pharm. Co., Ltd.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 7

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Overview 8

Therapeutics Development 9

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics under Development by Companies 11

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics under Investigation by Universities/Institutes 18

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline Products Glance 20

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Products under Development by Companies 24

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Products under Investigation by Universities/Institutes 33

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Companies Involved in Therapeutics Development 36

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Therapeutics Assessment 126

Drug Profiles 138

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects 380

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Discontinued Products 388

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Product Development Milestones 389

Appendix 401

List of Tables

List of Tables

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2016 28

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Comparative Analysis, H2 2016 29

Number of Products under Development by Companies, H2 2016 30

Number of Products under Development by Companies, H2 2016 (Contd..1) 31

Number of Products under Development by Companies, H2 2016 (Contd..2) 32

Number of Products under Development by Companies, H2 2016 (Contd..3) 33

Number of Products under Development by Companies, H2 2016 (Contd..4) 34

Number of Products under Development by Companies, H2 2016 (Contd..5) 35

Number of Products under Development by Companies, H2 2016 (Contd..6) 36

Number of Products under Investigation by Universities/Institutes, H2 2016 37

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 38

Comparative Analysis by Late Stage Development, H2 2016 39

Comparative Analysis by Clinical Stage Development, H2 2016 40

Comparative Analysis by Early Stage Development, H2 2016 41

Comparative Analysis by Unknown Stage Development, H2 2016 42

Products under Development by Companies, H2 2016 43

Products under Development by Companies, H2 2016 (Contd..1) 44

Products under Development by Companies, H2 2016 (Contd..2) 45

Products under Development by Companies, H2 2016 (Contd..3) 46

Products under Development by Companies, H2 2016 (Contd..4) 47

Products under Development by Companies, H2 2016 (Contd..5) 48

Products under Development by Companies, H2 2016 (Contd..6) 49

Products under Development by Companies, H2 2016 (Contd..7) 50

Products under Development by Companies, H2 2016 (Contd..8) 51

Products under Investigation by Universities/Institutes, H2 2016 52

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 53

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 54

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Absynth Biologics Limited, H2 2016 55

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Actelion Ltd, H2 2016 56

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Adenium Biotech ApS, H2 2016 57

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by AIMM Therapeutics B.V., H2 2016 58

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Alchemia Limited, H2 2016 59

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Allergan Plc, H2 2016 60

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by AlphaMab Co., Ltd, H2 2016 61

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Alvogen Korea Co., Ltd., H2 2016 62

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by AmpliPhi Biosciences Corporation, H2 2016 63

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by AnGes MG, Inc., H2 2016 64

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Antibiotx ApS, H2 2016 65

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Aphios Corporation, H2 2016 66

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Aridis Pharmaceuticals LLC, H2 2016 67

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Arsanis, Inc., H2 2016 68

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by AstraZeneca Plc, H2 2016 69

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Atriva Therapeutics GmbH, H2 2016 70

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Bavarian Nordic A/S, H2 2016 71

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Bharat Biotech International Limited, H2 2016 72

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by C3 Jian, Inc, H2 2016 73

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Cellceutix Corporation, H2 2016 74

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Cempra Inc, H2 2016 75

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Citius Pharmaceuticals, Inc., H2 2016 76

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Common Pharma Inc, H2 2016 77

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by ContraFect Corporation, H2 2016 78

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Crestone, Inc., H2 2016 79

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Critical Outcome Technologies Inc, H2 2016 80

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by CrystalGenomics, Inc., H2 2016 81

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by CSA Biotechnologies LLC , H2 2016 82

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Debiopharm International SA , H2 2016 83

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Dermala Inc, H2 2016 84

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by DesignMedix, Inc., H2 2016 85

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Destiny Pharma Limited, H2 2016 86

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 87

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by e-Therapeutics Plc, H2 2016 88

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Emergent BioSolutions Inc., H2 2016 89

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Ensol Biosciences Inc., H2 2016 90

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Excelimmune, Inc., H2 2016 91

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Galapagos NV, H2 2016 92

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by GangaGen Inc., H2 2016 93

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Gero Corp, H2 2016 94

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Helix BioMedix, Inc., H2 2016 95

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Hsiri Therapeutics LLC, H2 2016 96

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2016 97

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Immupharma Plc, H2 2016 98

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by iNtRON Biotechnology Inc., H2 2016 99

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by ioGenetics, Inc., H2 2016 100

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 101

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Lascco SA, H2 2016 102

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by LegoChem Biosciences, Inc, H2 2016 103

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Lipocure Ltd., H2 2016 104

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Madam Therapeutics B.V., H2 2016 105

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Melinta Therapeutics, Inc, H2 2016 106

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Merck & Co., Inc., H2 2016 107

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Microbiotix, Inc., H2 2016 108

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by MicuRx Pharmaceuticals, Inc., H2 2016 109

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by MorphoSys AG, H2 2016 110

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Motif Bio Plc, H2 2016 111

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Nabriva Therapeutics AG, H2 2016 112

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Nemus Bioscience, Inc., H2 2016 113

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Novabiotics Limited, H2 2016 114

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by NovaDigm Therapeutics, Inc., H2 2016 115

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by NovoBiotic Pharmaceuticals, LLC, H2 2016 116

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Omnia Molecular Ltd., H2 2016 117

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Oragenics, Inc., H2 2016 118

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Pfizer Inc., H2 2016 119

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Phico Therapeutics Limited, H2 2016 120

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Procarta Biosystems Limited, H2 2016 121

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Prommune, Inc., H2 2016 122

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Recce Pty Ltd, H2 2016 123

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Redx Pharma Plc, H2 2016 124

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Sarepta Therapeutics, Inc., H2 2016 125

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Savara Inc., H2 2016 126

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Sealife PHARMA GMBH, H2 2016 127

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Sentinella Pharmaceuticals, Inc., H2 2016 128

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Sequoia Sciences Inc, H2 2016 129

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Soligenix, Inc., H2 2016 130

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Sorrento Therapeutics Inc, H2 2016 131

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Taejoon Pharm Co., Ltd., H2 2016 132

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by TAXIS Pharmaceuticals, Inc., H2 2016 133

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Telephus Medical LLC, H2 2016 134

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Tetraphase Pharmaceuticals Inc., H2 2016 135

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by TGV-Laboratories, H2 2016 136

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Theravance Biopharma Inc, H2 2016 137

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Trellis Bioscience, Inc., H2 2016 138

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Valevia UK Limited, H2 2016 139

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by VLP Biotech, Inc., H2 2016 140

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Wintermute Biomedical LLC, H2 2016 141

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Wockhardt Limited, H2 2016 142

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by XBiotech Inc, H2 2016 143

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 144

Assessment by Monotherapy Products, H2 2016 145

Assessment by Combination Products, H2 2016 146

Number of Products by Stage and Target, H2 2016 148

Number of Products by Stage and Mechanism of Action, H2 2016 151

Number of Products by Stage and Route of Administration, H2 2016 154

Number of Products by Stage and Molecule Type, H2 2016 156

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects, H2 2016 399

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects (Contd..1), H2 2016 400

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects (Contd..2), H2 2016 401

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects (Contd..3), H2 2016 402

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects (Contd..4), H2 2016 403

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects (Contd..5), H2 2016 404

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects (Contd..6), H2 2016 405

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Dormant Projects (Contd..7), H2 2016 406

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Discontinued Products, H2 2016 407

List of Figures

List of Figures

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, H2 2016 28

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections Comparative Analysis, H2 2016 29

Number of Products under Development by Companies, H2 2016 30

Number of Products under Investigation by Universities/Institutes, H2 2016 37

Comparative Analysis by Clinical Stage Development, H2 2016 40

Comparative Analysis by Early Stage Products, H2 2016 41

Assessment by Monotherapy Products, H2 2016 145

Assessment by Combination Products, H2 2016 146

Number of Products by Top 10 Targets, H2 2016 147

Number of Products by Stage and Top 10 Targets, H2 2016 147

Number of Products by Top 10 Mechanism of Actions, H2 2016 150

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 150

Number of Products by Top 10 Routes of Administration, H2 2016 153

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 153

Number of Products by Top 10 Molecule Types, H2 2016 155

Number of Products by Stage and Top 10 Molecule Types, H2 2016 155

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports